“This new agreement with Sanofi Aventis is a strong endorsement of the ease of use and effectiveness of Autopen 24 in assisting patients in the management of their diabetes, acknowledged by healthcare professionals and patients alike,” said Adam Mumford, sales and marketing director at Owen Mumford. “Sanofi Aventis wants to provide maximum patient choice in the selection of the most appropriate insulin pen to suit individual needs and our partnership helps them achieve this goal.”